Page last updated: 2024-12-04

3-cyanopyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyridine-3-carbonitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-pyridinecarbonitrile : A nitrile that is pyridine substituted by a cyano group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID79
CHEMBL ID3181972
CHEBI ID86556
SCHEMBL ID28776
MeSH IDM0074766

Synonyms (67)

Synonym
AC-2424
AC-907/25014098
3-azabenzonitrile
ai3-15766
brn 0107711
einecs 202-863-0
hsdb 5335
nitryl kwasu nikotynowego [polish]
3-pyridinecarboxylic acid, nitrile
3-cyjanopirydyna [polish]
nsc 17558
3-pyridylcarbonitrile
nicotinonitrile
3-pyridinecarbonitrile
3-pyridinenitrile
nicotinic acid nitrile
nsc17558
nsc-17558
pyridine-3-carbonitrile
inchi=1/c6h4n2/c7-4-6-2-1-3-8-5-6/h1-3,5
100-54-9
3-CYANOPYRIDINE ,
3-pyridinecarbonitrile, 98%
STK046164
pyridine, 3-cyano-
6C16C9E3-90DC-4565-9F55-F6CC5D13CC33
BMSE000622
FT-0665307
AKOS000119616
NCGC00248004-02
NCGC00248004-01
ec 202-863-0
3-cyjanopirydyna
nitryl kwasu nikotynowego
unii-x64v0k6260
5-22-02-00115 (beilstein handbook reference)
x64v0k6260 ,
dtxcid606665
dtxsid1026665 ,
NCGC00259218-01
NCGC00254450-01
cas-100-54-9
tox21_201669
tox21_300354
bdbm92856
pnca inhibitor, 5
nicotinamidase inhibitor, 23
FT-0615558
AM81277
SCHEMBL28776
FG-0468
cyanopyridine, 3-
3-pyridinecarbonitrile [hsdb]
3-cyano pyridine
3-pyridyl cyanide
W-108955
chebi:86556 ,
CHEMBL3181972
F2108-0102
mfcd00006372
Z57899719
CS-0003918
Q18730591
EN300-18318
BBL037217
P19604
SB52234

Research Excerpts

Overview

3-Cyanopyridine is an excellent backbone for antitumor lead compounds, 10n and 9o. derivatives are excellent survivin protein-targeting inhibitors worthy of further study.

ExcerptReferenceRelevance
"3-Cyanopyridine is an excellent backbone for antitumor lead compounds, 10n and 9o, as derivatives of 3-Cyanopyridine are excellent survivin protein-targeting inhibitors worthy of further study. "( Design, Synthesis, and Molecular Docking Study of Novel 3-Cyanopyridine Derivatives for the Anti-Cancer Drug Target Survivin Protein.
Jiang, LH; Lai, WJ; Lei, FH; Lu, JH; Shen, LQ; Wu, AQ, 2023
)
2.6

Toxicity

ExcerptReferenceRelevance
" LD50 after oral administration amounts to 1185 mg/kg of body weight, 3-cyanpyridine is absorbed through the intact skin: administration of 3-cyanpyridine solution into rabbit skin caused death of animals."( [Evaluation of acute toxic effect of 3-cyanopyridine].
Knobloch, K; Majka, J; Szendzikowski, S, 1979
)
0.53

Dosage Studied

ExcerptRelevanceReference
" Males were dosed for 42 days beginning 14 days before mating, and females for 40-53 days beginning 14 days before mating to day 3 of lactation, including throughout the mating and gestation periods."( Reproductive and developmental toxicity screening test of 3-cyanopyridine in rats.
Hirata-Koizumi, M; Hirose, A; Kato, H; Kawamura, T; Matsumoto, M; Ono, A; Takahashi, M; Yabe, K, 2013
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
aldoxime degradation49

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency56.07160.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.84630.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency53.38520.000229.305416,493.5996AID743069
aryl hydrocarbon receptorHomo sapiens (human)Potency66.78650.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.13060.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency35.37880.000323.4451159.6830AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NicotinamidaseSaccharomyces cerevisiae S288CKi861.66670.01100.33061.4000AID1799844
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1799844GDH-Coupled Nicotinamidase Assay from Article 10.1021/bi1012518: \\Characterization of nicotinamidases: steady state kinetic parameters, classwide inhibition by nicotinaldehydes, and catalytic mechanism.\\2010Biochemistry, Dec-14, Volume: 49, Issue:49
Characterization of nicotinamidases: steady state kinetic parameters, classwide inhibition by nicotinaldehydes, and catalytic mechanism.
AID1799845Enzyme Assay from Article 10.1021/bi1011157: \\Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.\\2010Biochemistry, Nov-09, Volume: 49, Issue:44
Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.
AID1637723Stability of the compound assessed as half life for degradation2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
AID1637722Glutathione reactivity assessed as half life at 250 uM up to 72 hrs by HPLC-MS or NMR analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
AID1637721Glutathione reactivity assessed as thiol reactivity rate constant at 250 uM up to 72 hrs by HPLC-MS or NMR analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.88)18.7374
1990's3 (5.88)18.2507
2000's6 (11.76)29.6817
2010's31 (60.78)24.3611
2020's8 (15.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.77 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index46.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]